Published in Emerg Infect Dis on October 01, 2002
Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis (2002) 5.23
Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci Transl Med (2012) 2.17
Epidemiologic response to anthrax outbreaks: field investigations, 1950-2001. Emerg Infect Dis (2002) 2.08
Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg Infect Dis (2002) 2.03
Plant-based vaccine: mice immunized with chloroplast-derived anthrax protective antigen survive anthrax lethal toxin challenge. Infect Immun (2005) 1.64
Method for simultaneous measurement of antibodies to 23 pneumococcal capsular polysaccharides. Clin Diagn Lab Immunol (2003) 1.50
Public health in the time of bioterrorism. Emerg Infect Dis (2002) 1.46
Comparison of a multiplexed fluorescent covalent microsphere immunoassay and an enzyme-linked immunosorbent assay for measurement of human immunoglobulin G antibodies to anthrax toxins. Clin Diagn Lab Immunol (2004) 1.44
First case of bioterrorism-related inhalational anthrax in the United States, Palm Beach County, Florida, 2001. Emerg Infect Dis (2002) 1.34
Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol Mol Biol Rev (2004) 1.28
Mass value assignment of total and subclass immunoglobulin G in a human standard anthrax reference serum. Clin Diagn Lab Immunol (2004) 1.21
Interlaboratory comparison of results of an anthrax lethal toxin neutralization assay for assessment of functional antibodies in multiple species. Clin Vaccine Immunol (2008) 1.21
Short-course postexposure antibiotic prophylaxis combined with vaccination protects against experimental inhalational anthrax. Proc Natl Acad Sci U S A (2006) 1.18
Evaluation of immunogenicity and efficacy of anthrax vaccine adsorbed for postexposure prophylaxis. Clin Vaccine Immunol (2013) 1.17
The critical role of pathology in the investigation of bioterrorism-related cutaneous anthrax. Am J Pathol (2003) 1.17
Detection of anthrax toxin by an ultrasensitive immunoassay using europium nanoparticles. Clin Vaccine Immunol (2009) 1.15
Lethal factor toxemia and anti-protective antigen antibody activity in naturally acquired cutaneous anthrax. J Infect Dis (2011) 1.08
Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge. J Infect Dis (2010) 1.01
Anthrax vaccination induced anti-lethal factor IgG: fine specificity and neutralizing capacity. Vaccine (2011) 0.99
Evaluation of intravenous anthrax immune globulin for treatment of inhalation anthrax. Antimicrob Agents Chemother (2013) 0.98
Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. Clin Diagn Lab Immunol (2005) 0.98
Anthrax: A disease of biowarfare and public health importance. World J Clin Cases (2015) 0.97
The early humoral immune response to Bacillus anthracis toxins in patients infected with cutaneous anthrax. FEMS Immunol Med Microbiol (2011) 0.97
Rapid, sensitive, and specific lateral-flow immunochromatographic device to measure anti-anthrax protective antigen immunoglobulin g in serum and whole blood. Clin Vaccine Immunol (2006) 0.95
Nonhemolytic, nonmotile gram-positive rods indicative of Bacillus anthracis. Emerg Infect Dis (2003) 0.94
Comparison of three anthrax toxin neutralization assays. Clin Vaccine Immunol (2010) 0.92
Detection of Bacillus anthracis DNA in complex soil and air samples using next-generation sequencing. PLoS One (2013) 0.90
Recombinant protective antigen anthrax vaccine improves survival when administered as a postexposure prophylaxis countermeasure with antibiotic in the New Zealand white rabbit model of inhalation anthrax. Clin Vaccine Immunol (2012) 0.90
Anti-protective antigen IgG enzyme-linked immunosorbent assay for diagnosis of cutaneous anthrax in India. Clin Vaccine Immunol (2012) 0.89
Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adults. PLoS One (2010) 0.88
Immunoglobulin G (IgG) class, but Not IgA or IgM, antibodies to peptides of the Porphyromonas gingivalis chaperone HtpG predict health in subjects with periodontitis by a fluorescence enzyme-linked immunosorbent assay. Clin Vaccine Immunol (2009) 0.88
Anthrax Toxin-Expressing Bacillus cereus Isolated from an Anthrax-Like Eschar. PLoS One (2016) 0.87
Microproteinuria during Opisthorchis viverrini infection: a biomarker for advanced renal and hepatobiliary pathologies from chronic opisthorchiasis. PLoS Negl Trop Dis (2013) 0.86
Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin (2009) 0.86
Surface Plasmon Resonance Biosensor for Detection of Bacillus anthracis, the Causative Agent of Anthrax from Soil Samples Targeting Protective Antigen. Indian J Microbiol (2012) 0.86
Determination of serum IgG antibodies to Bacillus anthracis protective antigen in environmental sampling workers using a fluorescent covalent microsphere immunoassay. Occup Environ Med (2004) 0.83
Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis. Clin Vaccine Immunol (2011) 0.82
Antibody responses to a spore carbohydrate antigen as a marker of nonfatal inhalation anthrax in rhesus macaques. Clin Vaccine Immunol (2011) 0.82
Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. Vaccine (2014) 0.82
Zoonotic infections among employees from Great Smoky Mountains and Rocky Mountain National Parks, 2008-2009. Vector Borne Zoonotic Dis (2012) 0.81
Allelic-dependent expression of an activating Fc receptor on B cells enhances humoral immune responses. Sci Transl Med (2013) 0.81
Evaluation of early immune response-survival relationship in cynomolgus macaques after Anthrax Vaccine Adsorbed vaccination and Bacillus anthracis spore challenge. Vaccine (2016) 0.80
Rapid point-of-care test to detect broad ranges of protective antigen-specific immunoglobulin G concentrations in recipients of the U.S.-licensed anthrax vaccine. Clin Vaccine Immunol (2008) 0.80
Detection of anthrax protective antigen (PA) using europium labeled anti-PA monoclonal antibody and time-resolved fluorescence. J Immunol Methods (2014) 0.79
Recommended Immunological Assays to Screen for Ricin-Containing Samples. Toxins (Basel) (2015) 0.78
Humoral responses to independent vaccinations are correlated in healthy boosted adults. Vaccine (2014) 0.77
Development & validation of a quantitative anti-protective antigen IgG enzyme linked immunosorbent assay for serodiagnosis of cutaneous anthrax. Indian J Med Res (2015) 0.76
Optimization of ELISA conditions to quantify colorectal cancer antigen-antibody complex protein (GA733-FcK) expressed in transgenic plant. Monoclon Antib Immunodiagn Immunother (2014) 0.76
Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1/Alhydrogel hookworm vaccine. PLoS Negl Trop Dis (2017) 0.75
Unusual bacterial infections and the pleura. Open Respir Med J (2012) 0.75
Unique Inflammatory Mediators and Specific IgE Levels Distinguish Local from Systemic Reactions after Anthrax Vaccine Adsorbed Vaccination. Clin Vaccine Immunol (2016) 0.75
Bacillus anthracis Capsular Conjugates Elicit Chimpanzee Polyclonal Antibodies That Protect Mice from Pulmonary Anthrax. Clin Vaccine Immunol (2015) 0.75
Protective antigen-specific memory B cells persist years after anthrax vaccination and correlate with humoral immunity. Toxins (Basel) (2014) 0.75
Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate. Vaccine (2017) 0.75
Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated. Vaccine (2017) 0.75
Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis (2001) 11.73
Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA (2002) 10.40
Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis (1993) 4.74
Further purification studies on the protective antigen of Bacillus anthracis produced in vitro. J Bacteriol (1958) 3.29
Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay. J Clin Microbiol (1991) 2.42
Determination of parallelism and nonparallelism in bioassay dilution curves. J Clin Microbiol (1994) 2.40
Validation of serological assays for diagnosis of infectious diseases. Rev Sci Tech (1998) 2.33
Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect Immun (1986) 2.16
Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg Infect Dis (2002) 2.03
Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Med Microbiol Immunol (1988) 1.61
Opening a bacillus anthracis-containing envelope, Capitol Hill, Washington, D.C.: the public health response. Emerg Infect Dis (2002) 1.53
Purification and characterization of adenylyl cyclase from Bacillus anthracis. Methods Enzymol (1991) 1.48
Evaluation of serologic tests for diagnosis of anthrax after an outbreak of cutaneous anthrax in Paraguay. J Infect Dis (1989) 1.43
Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine (2002) 1.41
Collaborative calibration of the U. S. National and the College of American Pathologists reference preparations for specific serum proteins. Am J Clin Pathol (1982) 1.32
Comparison of enzyme-linked immunosorbent and indirect hemagglutination assays for determining anthrax antibodies. J Clin Microbiol (1984) 1.31
Serology and anthrax in humans, livestock and Etosha National Park wildlife. Epidemiol Infect (1992) 1.23
Human anthrax associated with an epizootic among livestock--North Dakota, 2000. MMWR Morb Mortal Wkly Rep (2001) 1.19
Anthrax indirect microhemagglutination test. J Immunol (1971) 1.19
Serological studies of patients with cutaneous and oral-oropharyngeal anthrax from northern Thailand. Am J Trop Med Hyg (1988) 1.19
Enzyme-linked immunosorbent assay using a recombinant baculovirus-expressed Bacillus anthracis protective antigen (PA): measurement of human anti-PA antibodies. Clin Diagn Lab Immunol (1994) 1.11
Safety and immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM197 conjugate vaccine in infants aged 15 to 23 months. Pediatrics (1990) 1.01
Antibiotics modulate vaccine-induced humoral immune response. Clin Diagn Lab Immunol (1999) 0.98
Update: Cutaneous anthrax in a laboratory worker--Texas, 2002. MMWR Morb Mortal Wkly Rep (2002) 0.96
Evaluation of the anthraxin skin test for diagnosis of acute and past human anthrax. Eur J Clin Microbiol Infect Dis (1996) 0.93
Serological diagnosis of anthrax. Lancet (1969) 0.90
Anthrax. Biological and immunological principles of diagnosis and prevention. Communication 7. Diagnosis of anthrax by means of anthraxin. J Hyg Epidemiol Microbiol Immunol (1973) 0.87
How well do serodiagnostic tests predict the infection or disease status of cats? J Am Vet Med Assoc (1991) 0.83
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med (2003) 15.48
IRE1 signaling affects cell fate during the unfolded protein response. Science (2007) 9.01
A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature (2009) 7.96
Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med (2006) 7.68
Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev (2002) 7.42
Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep (2002) 6.51
Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA (2008) 6.13
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet (2006) 5.56
Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis (2002) 5.23
Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med (2011) 5.21
A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med (2002) 4.88
Telomeres acquire embryonic stem cell characteristics in induced pluripotent stem cells. Cell Stem Cell (2009) 4.59
Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J Cell Biol (2009) 4.51
Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin Infect Dis (2002) 4.08
NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature (2012) 3.67
Therapies for active rheumatoid arthritis after methotrexate failure. N Engl J Med (2013) 3.51
U.S. outpatient antibiotic prescribing, 2010. N Engl J Med (2013) 3.49
Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis (2011) 3.46
An outbreak of conjunctivitis due to atypical Streptococcus pneumoniae. N Engl J Med (2003) 3.32
Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral pre-exposure prophylaxis for HIV-1 prevention. PLoS One (2011) 3.27
Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA (2002) 3.26
Determinants of per-coital-act HIV-1 infectivity among African HIV-1-serodiscordant couples. J Infect Dis (2012) 3.06
Evaluation of four commercially available rapid serologic tests for diagnosis of leptospirosis. J Clin Microbiol (2003) 3.01
Bacterial meningitis in the United States, 1998-2007. N Engl J Med (2011) 2.99
Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med (2011) 2.72
Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PLoS One (2010) 2.59
Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis. Antimicrob Agents Chemother (2008) 2.56
Epigenetic regulation of Nanog expression by Ezh2 in pluripotent stem cells. Cell Cycle (2011) 2.45
Viral linkage in HIV-1 seroconverters and their partners in an HIV-1 prevention clinical trial. PLoS One (2011) 2.36
Divergent effects of PERK and IRE1 signaling on cell viability. PLoS One (2009) 2.30
Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis (2004) 2.29
Seasonal patterns of invasive pneumococcal disease. Emerg Infect Dis (2003) 2.29
Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis (2007) 2.29
Evaluation of universal antenatal screening for group B streptococcus. N Engl J Med (2009) 2.25
Evaluation and validation of a real-time polymerase chain reaction assay for rapid identification of Bacillus anthracis. Emerg Infect Dis (2002) 2.23
Use of real-time PCR to resolve slide agglutination discrepancies in serogroup identification of Neisseria meningitidis. J Clin Microbiol (2004) 2.20
Pathology and pathogenesis of bioterrorism-related inhalational anthrax. Am J Pathol (2003) 2.11
Epidemiologic response to anthrax outbreaks: field investigations, 1950-2001. Emerg Infect Dis (2002) 2.08
Lower respiratory tract infections among american Indian and Alaska Native children and the general population of U.S. Children. Pediatr Infect Dis J (2005) 2.07
Application of TaqMan low-density arrays for simultaneous detection of multiple respiratory pathogens. J Clin Microbiol (2011) 2.07
Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med (2012) 2.06
Differential induction of the toll-like receptor 4-MyD88-dependent and -independent signaling pathways by endotoxins. Infect Immun (2005) 2.05
Superspreading SARS events, Beijing, 2003. Emerg Infect Dis (2004) 2.03
Inhalational anthrax outbreak among postal workers, Washington, D.C., 2001. Emerg Infect Dis (2002) 2.03
Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin Infect Dis (2005) 2.03
Outbreak of leptospirosis among triathlon participants and community residents in Springfield, Illinois, 1998. Clin Infect Dis (2002) 2.02
First confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in the United States, updated information on the epidemiology of MERS-CoV infection, and guidance for the public, clinicians, and public health authorities - May 2014. MMWR Morb Mortal Wkly Rep (2014) 2.00
Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol (2005) 2.00
Cationic antimicrobial peptide resistance in Neisseria meningitidis. J Bacteriol (2005) 1.99
Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med (2010) 1.99
Inactivation of Bacillus anthracis spores. Emerg Infect Dis (2003) 1.96
Risk factors for Buruli ulcer disease (Mycobacterium ulcerans Infection): results from a case-control study in Ghana. Clin Infect Dis (2005) 1.95
Chlorhexidine maternal-vaginal and neonate body wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, controlled trial. Lancet (2009) 1.95
Evaluation of three real-time PCR assays for detection of Mycoplasma pneumoniae in an outbreak investigation. J Clin Microbiol (2008) 1.93
Surveillance for unexplained deaths and critical illnesses due to possibly infectious causes, United States, 1995-1998. Emerg Infect Dis (2002) 1.89
Pharmacological brake-release of mRNA translation enhances cognitive memory. Elife (2013) 1.85
Histopathologic features of Mycobacterium ulcerans infection. Emerg Infect Dis (2003) 1.84
Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis (2003) 1.81
Trends in legionnaires disease, 1980-1998: declining mortality and new patterns of diagnosis. Clin Infect Dis (2002) 1.79
Influenza circulation and the burden of invasive pneumococcal pneumonia during a non-pandemic period in the United States. Clin Infect Dis (2010) 1.76
Comparative genomics of Neisseria meningitidis: core genome, islands of horizontal transfer and pathogen-specific genes. Microbiology (2006) 1.75
Plasma viral loads during early HIV-1 infection are similar in subtype C- and non-subtype C-infected African seroconverters. J Infect Dis (2013) 1.74
Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine. J Infect Dis (2005) 1.72
Perinatal infections due to group B streptococci. Obstet Gynecol (2004) 1.69
Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis (2005) 1.68
Changes in invasive Pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med (2006) 1.67
Bordetella holmesii bacteremia: a newly recognized clinical entity among asplenic patients. Clin Infect Dis (2004) 1.67
Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers. Cancer Epidemiol Biomarkers Prev (2003) 1.65
Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology (2002) 1.64
Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods (2008) 1.64
Outpatient antibiotic prescribing and nonsusceptible Streptococcus pneumoniae in the United States, 1996-2003. Clin Infect Dis (2011) 1.63